JNJ M&A Monday, November 16, 2026 +0.30 Positive

Johnson & Johnson Confirms It Will Acquire Ollin Biosciences To Increase Exposure To Serious Eye Disease Treatments For Initial Sum $2.2B And Up To ~$1.125B In Potential Milestones

Johnson & Johnson Confirms It Will Acquire Ollin Biosciences To Increase Exposure To Serious Eye Disease Treatments For Initial Sum $2.2B And Up To ~$1.125B In Potential Milestones

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed